NL-OMON31628招募中4 期
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. - CEPS
Sint Lucas Andreas Ziekenhuis0 个研究点目标入组 114 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 4 期
- 状态
- 招募中
- 发起方
- 入组人数
- 114
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •- Hemodialysis patient > 18 years
- •- Secondary hyperparathyoidism
排除标准
- •- Severe hypercalcemia (Ca2+ > 2,65 mmol/L)
- •- Severe hepatic dysfunction
- •- Overdosage of digoxin
- •- Hypersensitivity to vitamine D or an overdosage of vitamin D
- •- Parathyroidectomy
- •- < 18 years
- •- Pregnancy
- •- Mental illness
研究者
相似试验
进行中（未招募）
不适用
The (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidism in hemodialysis patients. - CEPSSecondary hyperparathyroidismMedDRA version: 9.1Level: LLTClassification code 10020708Term: Hyperparathyroidism secondaryEUCTR2007-006645-41-NLSint Lucas Andreas Hospital
尚未招募
不适用
Research to (cost)effectiveness of paricalcitol in the treatment of secondary hyperparathyroidismNL-OMON24070Het Sint Lucas Andreas ziekenhuis114
尚未招募
不适用
Research to cost-effectiveness of paricalcitol of the treatment of secundary hyperparathyroidism at hemodialysis patientsNL-OMON24822Sint Lucas Andreas ziekenhuis114
进行中（未招募）
不适用
Efficacy and safety of paricalcitol in the reduction of secondary hyperparathyroidism after kidney transplantation.Secondary hyperparathyroidism after renal transplantationMedDRA version: 16.0Level: PTClassification code 10020708Term: Hyperparathyroidism secondarySystem Organ Class: 10014698 - Endocrine disordersEUCTR2013-001326-25-ESFundación SENEFRO
终止
4 期
Efficacy and Safety of Paricalcitol on the Treatment of Secondary Hyperparathyroidism in Calcitriol Resistant Dialysis SubjectsSecondary HyperparathyroidismDialysisNCT00664430Abbott13